research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-08 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
=== Unclaimed property === After being elected treasurer, Kennedy drafted a bill to move the work of managing unclaimed property from the Department of Revenue to the state treasurer's office to allow him to continue the work he had started as secretary of revenue under Governor Foster. Kennedy led regular events to raise awareness about unclaimed property at malls and other public spaces, returning $400 million to 600,000 Louisianians. He told reporters that the state had returned money to many prominent Louisianians, including Foster, Archie Manning, and John Goodman. Under Kennedy's leadership, the treasury uncovered $45 million in unclaimed death benefits alone. With the money that remained unclaimed, Kennedy convinced the state legislature to establish a $200 million fund to repay construction bonds that were used to build I-49. He worked with Moody's and Standard & Poor's to maintain the state's favorable bond rating throughout the project.
Literary reflections of Cossack culture abound in Russian, Ukrainian, and Polish literature, particularly in the works of Nikolai Gogol (Taras Bulba), Taras Shevchenko, Mikhail Sholokhov (And Quiet Flows the Don), Henryk Sienkiewicz (With Fire and Sword). One of Leo Tolstoy's first novellas, The Cossacks, depicts their autonomy and estrangement from Moscow and from centralized rule. Many of Isaac Babel's stories (for instance, those in Red Cavalry) depict Cossack soldiers, and were based on Babel's experiences as a war correspondent attached to the 1st Cavalry Army. Polish Romantic literature also commonly dealt with Cossack themes. Some of the Polish writers of this period (for instance, Michał Czajkowski and Józef Bohdan Zaleski) were known as "Cossacophiles" who wholeheartedly celebrated the Cossack history and lifestyle in their works. Others, such as Henryk Rzewuski and Michał Grabowski, were more critical in their approach. In the literature of Western Europe, Cossacks appear in Byron's poem "Mazeppa", Tennyson's "The Charge of the Light Brigade", and Richard Connell's short story "The Most Dangerous Game". In many stories by adventure writer Harold Lamb, the main character is a Cossack. During the Imperial period, Cossacks acquired an image as the ferocious defenders of the antisemitic Russian state.
== Research development == In 1978 he began research at McGill on a dietary protein source that would boost immune system performance. Bounous contends that a deficiency in the protein glutathione is linked to several diseases, and that a lack of innate cysteine that inhibits glutathione production. Cysteine-Rich Protein Reverses Weight Loss in Lung Cancer Patients Receiving Chemotherapy or Radiotherapy Molecular pathogenesis and prevention of prostate cancer. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome.
Counterfeit drugs are a serious problem. People can potentially ingest useless or dangerous drugs without their knowledge. Custom package seals, authentication labels, holograms, and security printing can be valued parts of an entire security system. They help verify that enclosed drugs are what the package says they are. Drug counterfeiters, however, often work with package counterfeiters, some of whom can be sophisticated. No packaging system is completely secure.
Sources: en.wikipedia.org
GLOBSEC – Global think tank committed to enhancing security, prosperity and sustainability in Europe and throughout the world. Central European Labour Studies Institute or CELSI (Stredoeurópsky inštitút pre výskum práce in Slovak) – Central-european think tank which specializes in broadly defined labor issues, labour markets, and labor policy. Forum Minority Research Institute (Fórum Kisebbségkutató Intézet or Fórum Intézet in Hungarian and Fórum inštitút pre výskum menšín or Fórum inštitút in Slovak) – Think tank focusing on ethnic minorities living in Slovakia, especially Hungarians. International think tanks with presence in Slovakia:
Atmosphere of the Sun: in detectable trace amounts Atmosphere of Mercury: 3.4%, and large amounts of water in Mercury's exosphere Atmosphere of Venus: 0.002% Earth's atmosphere: ≈0.40% over full atmosphere, typically 1–4% at surface Atmosphere of the Moon: in trace amounts Atmosphere of Mars: 0.03% Atmosphere of Ceres Atmosphere of Jupiter: 0.0004% – in ices only; and that of its moon Europa Atmosphere of Saturn – in ices only; Enceladus: 91% and Dione (subsurface ocean) Atmosphere of Uranus – in trace amounts below 50 bar Atmosphere of Neptune – found in the deeper layers Extrasolar planet atmospheres: including those of HD 189733 b and HD 209458 b, Tau Boötis b, HAT-P-11b, XO-1b, WASP-12b, WASP-17b, and WASP-19b. Stellar atmospheres: not limited to cooler stars and even detected in giant hot stars such as Betelgeuse, Mu Cephei, Antares and Arcturus. Circumstellar disks: including those of more than half of T Tauri stars such as AA Tauri as well as TW Hydrae, IRC +10216 and APM 08279+5255, VY Canis Majoris and S Persei.
== Pathophysiology == In normal metabolism, the elevated blood glucose level causes beta (β) cells in the Islets of Langerhans, located in the pancreas, to release insulin into the blood. The insulin makes insulin-sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose which provides energy as well as lowers blood glucose, in a negative feedback loop. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a homeostatic constant level of approximately 5 mmol/L (90 mg/dL). In an insulin-resistant individual, normal levels of insulin do not have the same effect in controlling blood glucose levels. When the body produces insulin under conditions of insulin resistance, the cells are unable to absorb or use glucose as effectively and it stays in the bloodstream. Certain cell types such as fat and muscle cells require insulin to absorb glucose and when these cells fail to respond adequately to circulating insulin, blood glucose levels rise. Skeletal muscle is thought to be particularly important in this regard. The liver normally helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. However, in insulin resistance, this normal reduction in the liver's glucose production may not occur, further contributing to elevated blood glucose. Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels.
=== Regulation === In vertebrates, the secretion of melatonin is regulated through the activation of the beta-1 adrenergic receptor by the hormone norepinephrine. Norepinephrine increases the concentration of intracellular cAMP via beta-adrenergic receptors, which in turn activates the cAMP-dependent protein kinase A (PKA). PKA then phosphorylates arylalkylamine N-acetyltransferase (AANAT), the penultimate enzyme in the melatonin synthesis pathway. When exposed to daylight, noradrenergic stimulation ceases, so AANAT is not phosphorylated. In the absence of phosphorylation, AANAT is immediately degraded by proteasomal proteolysis. Blue light, especially within the 460–480 nm range, inhibits the biosynthesis of melatonin, with the degree of suppression being directly proportional to the intensity and duration of light exposure. Historically, humans in temperate climates experienced limited exposure to blue daylight during winter months, primarily receiving light from sources that emitted predominantly yellow light, such as fires. The incandescent light bulbs used extensively throughout the 20th century emitted relatively low levels of blue light. It has been found that light containing only wavelengths greater than 530 nm does not suppress melatonin under bright-light conditions. The use of glasses that block blue light in the hours preceding bedtime can mitigate melatonin suppression.
== Overview == The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) who work on very early-stage drug development on very small scale providing medicinal chemistry services. These are now often called CDROs as they provide some small scale development work. CDMOs work on the scale-up and later stages of drug development often preparing materials ranging from hundreds of grams to multi-kilo amounts. As the drug moves through the various clinical stages, the volumes tend to grow as well. Commercial scale amounts could range to metric tons. Over the years, the concept of a comprehensive single-source provider from drug development (a one-stop shop) through commercial manufacture of drug substance and drug product has been tried to varying success. CDMOs are a response to the competitive international nature of the pharmaceutical market as well as the increasing demand for outsourced services. The best-positioned service providers focus on a specific technology or dosage form and promote end-to-end continuity and efficiency for their outsourcing clients. With lower-cost international manufacturers capturing an increasing percentage of the contract manufacturing market, specialization may be an effective hedge against loss of market share.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.